Cost-effectiveness and budget impact analysis of PPV23 vaccination for the Malaysian Hajj pilgrims

被引:1
|
作者
Aminuddin, Farhana [1 ]
Zaimi, Nur Amalina [1 ]
Kunusagaran, Mohd Shaiful Jefri Mohd Nor Sham [1 ]
Bahari, Mohd Shahri [1 ]
Hassan, Nor Zam Azihan Mohd [1 ]
机构
[1] Minist Hlth Malaysia, Inst Hlth Syst Res, Shah Alam, Selangor, Malaysia
来源
PLOS ONE | 2022年 / 17卷 / 01期
关键词
PNEUMOCOCCAL POLYSACCHARIDE VACCINE; STREPTOCOCCUS-PNEUMONIAE; INVASIVE DISEASE; SAUDI-ARABIA; SURVEILLANCE; INFECTIONS; PATTERN; ADULTS;
D O I
10.1371/journal.pone.0262949
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The potential occurrence of disease outbreaks during the hajj season is of great concern due to extreme congestion in a confined space. This promotes the acquisition, spread and transmission of pathogenic microorganisms and pneumococcal disease are one of the most frequent infections among Hajj pilgrims. This study aimed to assess the cost-effectiveness and budget impact of introducing the PPV23 to Malaysian Hajj pilgrims. A decision tree framework with a 1-year cycle length was adapted to evaluate the cost-effectiveness of a PPV23 vaccination program with no vaccination. The cost information was retrieved from the Lembaga Tabung Haji Malaysia (LTH) database. Vaccine effectiveness was based on the locally published data and the disease incidence specifically related to Streptococcus pneumoniae was based on a literature search. Analyses were conducted from the perspective of the provider: Ministry of Health and LTH Malaysia. The incremental cost-effectiveness ratios (ICER), cases averted, and net cost savings were estimated. Findings from this study showed that PPV23 vaccination for Malaysian Hajj pilgrims was cost-effective. The PPV23 vaccination programme has an ICER of MYR -449.3 (US$-110.95) per case averted. Based on the national threshold value of US$6,200-US$8,900 per capita, the base-case result shows that introduction of the PPV23 vaccine for Malaysian Hajj pilgrims is very cost-effective. Sensitivity analysis revealed parameters related to annual incidence and hospitalised cost of septicemia and disease without vaccination as the key drivers of the model outputs. Compared with no vaccination, the inclusion of PPV23 vaccination for Malaysian Hajj pilgrims was projected to result in a net cost saving of MYR59.6 million and 109,996 cases averted over 5 years period. The PPV23 vaccination program could substantially offer additional benefits in reducing the pneumococcal disease burden and healthcare cost. This could be of help for policymakers to consider the implementation of PPV23 vaccination for Malaysian performing hajj.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] A COST-EFFECTIVENESS ANALYSIS OF VACCINATING THE ELDERLY WITH 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) IN GERMANY
    Jiang, Y.
    Gauthier, A.
    Annemans, L.
    van der Linden, M.
    Nicolas-Spony, L.
    Bresse, X.
    VALUE IN HEALTH, 2011, 14 (07) : A279 - A279
  • [2] A COST-EFFECTIVENESS ANALYSIS OF REVACCINATING OLDER ADULTS WITH THE 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) COMPARED TO VACCINATING WITH A SINGLE DOSE OF PPV23 IN THE UNITED KINGDOM (UK)
    Jiang, Y.
    Yang, X.
    Mahajan, S.
    Gupta, R.
    Matthews, I. R.
    VALUE IN HEALTH, 2018, 21 : S228 - S228
  • [3] COST-EFFECTIVENESS ANALYSIS OF VACCINATION WITH 13-VALENT CONJUGATE (PCV13) AND 23-VALENT (PPV23) POLYSACCHARIDE PNEUMOCOCCAL VACCINES FOR ADULTS IN SWEDEN
    Dorange, A.
    Nyman, L.
    VALUE IN HEALTH, 2016, 19 (03) : A216 - A217
  • [4] A SISTEMATIC REVIEW OF THE COST-EFFECTIVENESS OF VACCINATING ELDERLY WITH THE 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23)
    Nishikawa, A. M.
    Mainardi, G. M.
    Novaes, H. M.
    Sartori, A. M.
    De Soarez, P. C.
    VALUE IN HEALTH, 2017, 20 (09) : A932 - A932
  • [5] Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in Denmark compared with PPV23
    Olsen, Jens
    Schnack, Henrik
    Skovdal, Mette
    Vietri, Jeffrey
    Mikkelsen, Malene Buch
    Poulsen, Peter Bo
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 1240 - 1254
  • [6] COST-EFFECTIVENESS OF REPLACING THE SEQUENCE PCV13/PPV23 WITH PCV20 IN THE FRENCH ADULT PNEUMOCOCCAL VACCINATION PROGRAM
    Fievez, S.
    Blanc, E.
    Bougeois, M.
    Sivignon, M.
    Supiot, R.
    Vietri, J.
    Perdrizet, J.
    Bellier, L.
    VALUE IN HEALTH, 2023, 26 (12) : S78 - S78
  • [7] A COST-EFFECTIVENESS ANALYSIS OF VACCINATING THE ELDERLY WITH THE 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) COMPARED TO NO VACCINATION, THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13), OR PCV13 FOLLOWED BY PPV23 IN BRAZIL
    Jiang, Y.
    Yang, X.
    Petigara, T.
    Chabrol Haas, L.
    Graham, J.
    VALUE IN HEALTH, 2017, 20 (09) : A930 - A930
  • [8] A cost-effectiveness analysis of vaccinating older adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) compared to no vaccination, the 13-valent pneumococcal conjugate vaccine (PCV13), or PCV13 followed by PPV23 in Colombia
    Prieto, E.
    Jiang, Y.
    Yang, X.
    Graham, J. B.
    Monsanto, H.
    Ruiz, J.
    Beltran, C.
    Rojas, M.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2018, 73 : 13 - 13
  • [9] Cost-Effectiveness and Budget Impact Analyses of Pneumococcal Vaccination in Indonesia
    Suwantika, Auliya A.
    Zakiyah, Neily
    Abdulah, Rizky
    Sitohang, Vensya
    Tandy, Gertrudis
    Anartati, Atiek
    Hidayatullah, Tetrawindu
    Herliana, Putri
    Hadinegoro, Sri R.
    JOURNAL OF ENVIRONMENTAL AND PUBLIC HEALTH, 2021, 2021
  • [10] Cost-effectiveness and budget impact analyses of dengue vaccination in Indonesia
    Suwantika, Auliya Abdurrohim
    Supadmi, Woro
    Ali, Mohammad
    Abdulah, Rizky
    PLOS NEGLECTED TROPICAL DISEASES, 2021, 15 (08):